) recently entered into an agreement with ConfometRx for the
discovery of novel medicines in the neuroscience therapeutic
area. This research and development (R&D) collaboration,
spanning two years, will harness structural biology to gain
insight into G protein coupled receptors (GPCRs) modulation in
ConfometRx is developing a platform of structure-based drug
discovery technologies to facilitate lead identification and lead
optimization for GPCR.
UCB also has R&D alliances with Harvard. UCB and Harvard
have three collaborative R&D projects since 2011. In Oct
2012, the third project was signed to study the microbiome in the
human intestine, classifying new species and studying their
impact on the immune system in order to identify new drugs for
preventing or treating immunological diseases. For this study,
UCB will provide Harvard up to $4.5 million.
The major neuroscience products at UCB include Vimpat
(lacosamide) and Neupro (rotigotine). Vimpat and Neupro revenues
for the nine months ending Sep 30, 2012 were € 237 million and €
93 million respectively.
In Dec 2012, UCB received Japanese approval for Neupro for
Parkinson's disease and restless legs syndrome. The drug was
approved in the EU and US in 2006 and 2007, respectively.
Vimpat was first launched in the EU in Sep 2008, as an adjunctive
therapy for treating adults and adolescents (16-18 years)
suffering from partial-onset seizures (with or without secondary
generalization) with epilepsy.
Earlier this month, Vimpat was approved in the EU as a single
loading dose option for treating patients suffering from partial
UCB carries a Zacks Rank #3 (Hold). Currently, companies like
Lannett Company, Inc.
SIGA Technologies, Inc.
United Therapeutics Corporation
) look more attractive with a Zacks Rank #1 (Strong Buy).
LANNETT INC (LCI): Free Stock Analysis Report
SIGA TECH INC (SIGA): Free Stock Analysis
UCB SA (UCBJF): Get Free Report
UTD THERAPEUTIC (UTHR): Free Stock Analysis
To read this article on Zacks.com click here.